These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30198909)

  • 1. NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell.
    Dunai C; Murphy WJ
    J Clin Invest; 2018 Oct; 128(10):4251-4253. PubMed ID: 30198909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
    Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
    J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK Cells Respond to Checkpoint Blockade.
    Cancer Discov; 2018 Dec; 8(12):1498. PubMed ID: 30352860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.
    Liu Y; Cheng Y; Xu Y; Wang Z; Du X; Li C; Peng J; Gao L; Liang X; Ma C
    Oncogene; 2017 Nov; 36(44):6143-6153. PubMed ID: 28692048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death protein 1 on natural killer cells: fact or fiction?
    Cho MM; Quamine AE; Olsen MR; Capitini CM
    J Clin Invest; 2020 Jun; 130(6):2816-2819. PubMed ID: 32391808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.
    Song M; Huang Y; Hong Y; Liu J; Zhu J; Lu S; Wang J; Sun F; Huang J; Xu J; Tang Y; Xia JC; Zhang Y
    Oncoimmunology; 2024; 13(1):2289738. PubMed ID: 38125723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.
    Huang BY; Zhan YP; Zong WJ; Yu CJ; Li JF; Qu YM; Han S
    PLoS One; 2015; 10(8):e0134715. PubMed ID: 26266810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy.
    Bai R; Cui J
    Front Immunol; 2022; 13():886931. PubMed ID: 35634343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 blocks lytic granule polarization with concomitant impairment of integrin outside-in signaling in the natural killer cell immunological synapse.
    Huang Y; Chen Z; Jang JH; Baig MS; Bertolet G; Schroeder C; Huang S; Hu Q; Zhao Y; Lewis DE; Qin L; Zhu MX; Liu D
    J Allergy Clin Immunol; 2018 Oct; 142(4):1311-1321.e8. PubMed ID: 29679656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
    Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cells limit therapeutic vaccine-induced CD8
    Diniz MO; Schurich A; Chinnakannan SK; Duriez M; Stegmann KA; Davies J; Kucykowicz S; Suveizdyte K; Amin OE; Alcock F; Cargill T; Barnes E; Maini MK
    Sci Transl Med; 2022 Apr; 14(640):eabi4670. PubMed ID: 35417187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
    Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB
    J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
    Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
    J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
    Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
    ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance.
    Del Rio ML; Perez-Simon JA; Rodriguez-Barbosa JI
    Front Immunol; 2022; 13():887348. PubMed ID: 35795681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
    Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
    Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.